Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703002 | 0.89 | NLRP3 (1.00) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL7976076 | 0.85 | NLRP3 (0.60) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL22390769 | 0.83 | NLRP3 (0.61) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL9359788 | 0.81 | NLRP3 (0.78) | NLRP3SMN1; SMN2KDM4EGLAPOLB | |
| SCHEMBL4820340 | 0.81 | ALDH1A1 (0.59) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL4825037 | 0.81 | NLRP3 (0.58) | NLRP3SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL26181223 | 0.81 | NLRP3 (0.68) | NLRP3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4826133 | 0.81 | ALDH1A1 (0.62) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL7558526 | 0.79 | NLRP3 (0.54) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1985207 | 0.79 | NLRP3 (0.54) | NLRP3SMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7439382-B2 | 4-alkyl-2-haloaniline derivatives and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20050143454-A1 | 4-Alkyl-2-haloaniline derivative and process and process for producing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1506954-A1 | 4-ALKYL-2-HALOANILINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NLRP3 1659/4885SMN1; SMN2 3787/4885NPC1 3130/4885 |
| US-20050143454-A1 | 4-Alkyl-2-haloaniline derivative and process and process for producing the same | NAT1, CYP4X1, HAX1 | NLRP3 3421/4885SMN1; SMN2 4051/4885NPC1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.